EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever - AOL
3 Best Dividend Stocks for a $100,000 Passive Income Strategy
Johnson & Johnson Reports Lower Mortality Rates in Impella-Supported High-Risk Coronary Procedures
Johnson & Johnson $JNJ Stock Bought by MGO One Seven LLC
Johnson & Johnson $JNJ Stock Position Raised by Modera Wealth Management LLC
Johnson & Johnson $JNJ Shares Bought by Summit Global Investments - Daily Political
Vertex Pharmaceuticals News | Markets Insider
Promising Healthcare Stocks To Research - November 1st - Markets Daily
4 Blue-Chip Dividend Stocks That Kept Raising Payouts Through 2008 and 2020
4,626 Johnson & Johnson $JNJ Shares Purchased by Soltis Investment Advisors LLC - Zolmax
VIRGINIA RETIREMENT SYSTEMS ET Al Sells 21,400 Shares of Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Stock Acquired by Partners Wealth Management LLC
Johnson & Johnson $JNJ Stock Holdings Lowered by Interchange Capital Partners LLC
Johnson & Johnson $JNJ Stock: D.A. Davidson & CO. Decreases Holdings
Blueprint Financial Advisors LLC Buys New Shares in Johnson & Johnson $JNJ
Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy?
Johnson & Johnson $JNJ Stock Bought by Founders Financial Securities LLC - Stock Observer
Is Johnson & Johnson (JNJ) Cheap On Pipeline Wins Or Is The Upside Priced In? - Simply Wall St News
If a Bear Market Is Coming, History Says These Stocks Could Be the Smartest to Own
Promising Pharmaceutical Stocks To Follow Today - October 31st - Stock Observer
Johnson & Johnson $JNJ Stock: VestGen Advisors LLC Lowers Position
Johnson & Johnson $JNJ Holdings Decreased by Simplify Asset Management Inc.
Johnson & Johnson $JNJ Stock Position Lowered by Bokf Na
Johnson & Johnson $JNJ Stock Position Cut by Busey Bank
Johnson & Johnson $JNJ Stock Sold by LaFleur & Godfrey LLC - Stock Observer
How Investors Are Reacting To Johnson & Johnson Stock New Drug Progress
Johnson & Johnson (JNJ) Stock May Be 42% Undervalued Despite Cancer Trial Results - Simply Wall St News
No Tricks, Just Treats: 3 Dividend Stocks With Payouts You Can Trust
Johnson & Johnson (NYSE:JNJ) Reaches New 12-Month High - Still a Buy?
CDs Offer Fixed Interest. AbbVie Offers a Growing Dividend. Which Should Retirees Choose?
Johnson & Johnson $JNJ Holdings Increased by Oppenheimer & Co. Inc.
Johnson & Johnson $JNJ Stock Position Lifted by Verdence Capital Advisors LLC
Johnson & Johnson $JNJ Stake Trimmed by Miller Howard Investments Inc. NY
Verdence Capital Advisors LLC Purchases 8,909 Shares of Johnson & Johnson $JNJ
Head and Neck Squamous Cell Carcinoma Market Size in the 7MM is projected to reach nearly USD 2,560 million by 2036, growing at a CAGR of 10.5% during 2026-2036 | DelveInsight | ABNewswire
Johnson & Johnson (NYSE:JNJ) Stock Jumps 1.5% - Here's What Happened
Does Johnson & Johnson (JNJ) Have A New Edge In Plaque Psoriasis?
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher
4 Dividend-Paying Dow Jones Industrial Stocks That Beat Q3 Estimates
3 Unstoppable S&P 500 Stocks to Buy Before October Ends - AOL
104,967 Shares in Johnson & Johnson $JNJ Purchased by Leo Wealth LLC
Johnson & Johnson $JNJ Position Lifted by Sigma Planning Corp
Apollon Wealth Management LLC Purchases 10,233 Shares of Johnson & Johnson $JNJ
Why Domestic CAR-T Therapies Are Fiercely Sought After by Investors Amid Overseas Biotech R&D Cuts & Surging Domestic Capital Inflows
Merck News | Markets Insider
Top Pharmaceutical Stocks To Follow Now - October 28th - Zolmax
Why JEPI's Total Return Has Outpaced Its Payout
What State Street Health Care SPDR (XLV) Bought: Eli Lilly Leads on Oct. 26
Johnson & Johnson $JNJ Shares Sold by Norris Perne & French LLP MI
Johnson & Johnson (JNJ) Shows Over 75% Response Rates In Two Cancer Trials - Simply Wall St News
Head to Head Review: Johnson & Johnson (NYSE:JNJ) & Zoetis (NYSE:ZTS) - Stock Observer
FY2027 EPS Forecast for Johnson & Johnson Lowered by Analyst - Zolmax
Johnson & Johnson $JNJ Shares Bought by Signaturefd LLC - Daily Political
One Wealth Capital Management LLC Purchases 4,190 Shares of Johnson & Johnson $JNJ - Daily Political
Dakota Johnson sold 3,210 square feet midcentury modern home in Los Angeles for $5.924 million
Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
Pharmaceutical Stocks To Research - October 27th - Zolmax
CDs or Dividend Stocks: Which Pays Retirees Better Right Now?
Medtronic Quietly Raised Its Dividend Again. Is It a Buy for Income Investors?
Cerebras Systems Inc. $CBRS Stock Purchased by Johnson & Johnson
Johnson & Johnson $JNJ Shares Purchased by RWC Asset Management LLP - Stock Observer
Johnson & Johnson $JNJ Stock: RWC Asset Management LLP Increases Stake
Johnson & Johnson (NYSE:JNJ) Stock Crosses Above 50 Day Moving Average - Here's Why
15,883 Johnson & Johnson $JNJ Shares Sold by Capital Investment Advisors LLC
Barrett & Company Inc. Acquires 50,741 Shares of Johnson & Johnson $JNJ
Johnson & Johnson (NYSE:JNJ) Stock Has Average Price Target of $275.92 According to Analysts - Daily Political
What Do Johnson & Johnson (JNJ) Cancer Trial Wins Mean For Its Stock?
Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026-2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight
Johnson & Johnson Reports Phase 1 Prostate Cancer Drug Results at ESMO 2026
Forget Chasing High Yields: These 4 Dividend Kings Play the Long Game
2 Safe S&P 500 Dividend Stocks Boomers Can Buy and Hold Forever
J&J's RYBREVANT FASPRO Combo Delivers 77% Response Rate In Head And Neck Cancer
ETFs Are Net Sellers of Johnson & Johnson (JNJ) on Oct. 22
NBT Bank N.A. Buys 102,588 Shares of Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Stock Sold by SeaCrest Wealth Management LLC
Johnson & Johnson $JNJ Shares Sold by Brookstone Capital Management
Johnson & Johnson $JNJ Stock: Boomfish Wealth Group LLC Cuts Stake
Johnson & Johnson Posts Positive Phase 1b/2 Data Of Amivantamab Combo In Head And Neck Cancer
Promising Results from Johnson & Johnson's New Prostate Cancer Drug, ETPharma
Johnson & Johnson announces Phase 1 results for JNJ-6143 at ESMO 2026
Johnson & Johnson announces results from Cohort 5 of Phase 1b/2 OrigAMI-4 study
Johnson & Johnson announces results from Phase 3 PROTEUS substudy
T-Bills Yield Up to 4.45%. Why Would Retirees Choose Dividend Stocks?
Promising Healthcare Stocks To Keep An Eye On - October 25th - Markets Daily
Smith & Nephew (LSE:SN.) Stays Independent, Is It 8% Undervalued?
J&J's RYBREVANT FASPRO Regimen Delivers 77% Response Rate In First-Line HNSCC Study
Smith & Nephew (LSE:SN.) Stock May Be 34% Below Fair Value As Merger Talks Collapse
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer | Morningstar
Johnson & Johnson (JNJ) Reports 69% Tumor Response Rate for Prostate Cancer Drug
7,129 Johnson & Johnson $JNJ Shares Sold by Smith Chas P & Associates PA Cpas
23,454 Johnson & Johnson $JNJ Shares Sold by Vest Financial LLC
Johnson & Johnson $JNJ Stock Sold by Investment House LLC
Johnson & Johnson $JNJ Stock: Lmcg Investments LLC Decreases Stake - Stock Observer
SBI Securities Co. Ltd. Acquires 10,021 Shares of Johnson & Johnson $JNJ - Daily Political
JnJ News
Boeing Stock Forecast 2026–2030: Can a Record $745 Billion Backlog Reverse BA’s 11% Earnings Sell-Off?
CoreWeave Stock Forecast 2026–2030: Can CRWV Recover From the AI Debt Sell-Off?
Nebius Stock Price Prediction 2026–2030: Can AI Cloud Growth Justify the Cost?
Latest news
Show more
Gold Price Today: Gold Reclaims $3,900 as Fed Rate Concerns Weigh on Recovery
Palantir Q3 Earnings Preview: Can AI Growth Support PLTR’s Valuation?
AMD Earnings Preview: Can AI Chip Growth Reverse the Stock’s 11% Sell-Off?
Gold Price Forecast This Week: Can XAU/USD Recover After Crashing Below $3,900?
Intel Stock Plunges About 30% as Alphabet Sell-Off Deepens AI Spending Concerns
